All studies included in the meta-analyses consistently confirmed the significant association of MRD status with overall survival (OS) and progression free survival (PFS). The predictive value of MRD status was shown to be independent of study design, MRD assessment and type of treatment used.

A narrow prediction interval indicated the benefit of MRD testing in the prediction of PFS; however, lack of high-quality estimates for OS resulted in some uncertainty.

These results support the role of MRD status as a surrogate endpoint for outcomes in patients with CLL.

Weird not to go to an actual meeting, but needs must !​